ArticleMolecular biology reports2026
SNP-Driven LncRNA H19 dysregulation and CeRNA axis in breast and thyroid cancers among Pakistani females.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-Omics Analysis of the Effects ofInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) and Thyroid cancer (TC) are prevalent malignancies in women that share epidemiological and molecular features. Emerging evidence indicates that non-coding RNAs are key regulators of cancer associated gene expression. Long non-coding RNA (lncRNA) drive tumor progression by acting as competing endogenous RNAs (ceRNAs), sponging microRNA (miRNA) to deregulate oncogenic messenger RNA (mRNA). The influence of functional genetic polymorphisms of lncRNAs on their expression, as well as the expression of their ceRNA components RNA in a direct comparative context of BC and TC, remains unexplored.
methods60 breast cancer and 60 thyroid cancer tissue samples, alongside matched adjacent healthy controls from a Pakistani female patient, were used. Genotyping of lncRNA H19 SNPs (rs3741219 and rs2839698) was performed using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) followed by quantitative real-time PCR (qRT-PCR) to assess the expression of lncRNA H19, miR-152, and DNMT1. Expression and genotype associations, association with clinical parameters, and diagnostic and prognostic utility of the studied RNA were statistically evaluated.
resultGenotyping revealed that rs3741219 showed significant tumor-control differences in breast cancer (p < 0.05). Expression analysis revealed upregulation of lncRNA H19 and DNMT1, and downregulation of miR-152, in tumor samples compared with adjacent healthy controls in both cancers. In genotype-expression analysis, rs3741219 influenced lncRNA H19 expression in both cancer types. Receiver Operating Characteristic (ROC) analysis confirmed the strong diagnostic potential of H19 and DNMT1 (AUC 0.98-1.00). Correlation and regression analyses validated the proposed ceRNA interactions and their significant association with advanced cancer stage. A high-risk score from the H19/miR-152/DNMT1 axis was prognostic only in thyroid cancer (HR = 2.97).
Indexed as
Identifiers
41721915What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.